Kukar Lab Publishes Paper in Journal of Experimental Medicine
The Kukar lab published a paper titled, "Short Aβ peptides attenuate Aβ42 toxicity in vivo," in the Journal of Experimental Medicine.
Author Information:
Moore B.D., Martin J., de Mena L., Sanchez J., Cruz P.E., Ceballos-Diaz C., Ladd T.B., Yong R., Levites Y., Kukar T.L., Kurian J.J., McKenna R., Koo E.H., Borchelt D.R., Janus C., Rincon-Limas D., Fernandez-Funez P., Golde T.E.
Processing of amyloid-β (Aβ) precursor protein (APP) by γ-secretase produces multiple species of Aβ: Aβ40, short Aβ peptides (Aβ37-39), and longer Aβ peptides (Aβ42-43). γ-Secretase modulators, a class of Alzheimer's disease therapeutics, reduce production of the pathogenic Aβ42 but increase the relative abundance of short Aβ peptides. To evaluate the pathological relevance of these peptides, we expressed Aβ36-40 and Aβ42-43 in Drosophila melanogaster to evaluate inherent toxicity and potential modulatory effects on Aβ42 toxicity. In contrast to Aβ42, the short Aβ peptides were not toxic and, when coexpressed with Aβ42, were protective in a dose-dependent fashion. In parallel, we explored the effects of recombinant adeno-associated virus-mediated expression of Aβ38 and Aβ40 in mice. When expressed in nontransgenic mice at levels sufficient to drive Aβ42 deposition, Aβ38 and Aβ40 did not deposit or cause behavioral alterations. These studies indicate that treatments that lower Aβ42 by raising the levels of short Aβ peptides could attenuate the toxic effects of Aβ42.